India's cancer market booms with new therapies

23 February 2025

India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a rising cancer burden and demand for cutting-edge treatments. Leading the charge are big domestic pharma spearheading the launch of breakthrough oncology drugs. Not to be outdone are global innovators, stepping up to meet the growing demand for advanced oncology care, reports The Pharma Letter’s India correspondent.

Among the new drugs launched in India over the past 12 months, AstraZeneca’s LSE: AZN) Enhertu (trastuzumab deruxtecan) has emerged as the highest-selling brand. According to IQVIA data as of MAT December 2024, Enhertu generated sales of $6.68 million, surpassing all other new drug introductions in the market.

Enhertu's success can be attributed to its unique mechanism of action and its proven efficacy in treating HER2-positive breast cancer, said an analyst. The drug's ability to deliver targeted therapy with fewer side effects compared to traditional chemotherapy has made it a preferred option for many patients and oncologists, she added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK